BOTHELL, Wash.--(BUSINESS WIRE)--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced the initiation of a Phase 1 clinical study for its second oncology product candidate, TOCOSOL® Camptothecin, a novel camptothecin drug. Formulated with the Company’s proprietary vitamin E-based TOCOSOL technology, TOCOSOL Camptothecin is a New Chemical Entity that is a conjugate of SN-38. SN-38 is the active ingredient in irinotecan, a commercially available camptothecin analog. Preclinical data, presented at the AACR-NCI-EORTC 2005 conference, suggest that TOCOSOL Camptothecin may be more efficacious and better tolerated than irinotecan.
